Traders should monitor enrollment and event accumulation rates in the DECLARATION study, as well as regulatory interactions for VMS063. The delay in VYD2311 results reduces near-term catalyst visibility, while VMS063 represents a high-risk, high-reward pipeline expansion into a new indication.
Price Chart
Executive Summary
Invivyd announced progress in its Phase 3 DECLARATION study for VYD2311, including a pre-specified upsizing by ~500 subjects to ensure robust statistical power, pushing top-line results to Q3 2026. The company also announced the advancement of VMS063, a novel measles monoclonal antibody candidate, with IND readiness targeted for late 2026.
Key Facts
- DECLARATION Phase 3 study upsized by ~500 subjects, increasing total enrollment beyond initial 1,818.
- Top-line results for VYD2311 now expected in Q3 2026, a two-month delay from prior 'mid-year' guidance.
- FDA alignment on initial Pediatric Study Plan (DRUMMER trial) for VYD2311 in children aged 0-11, contingent on adult trial success.
- VMS063, a novel measles mAb candidate, advanced toward IND-enabling studies with target IND readiness in late 2026.
- No clinical efficacy or safety data reported for either VYD2311 or VMS063; all updates are developmental and forward-looking.
Financial Impact
No immediate financial impact disclosed; long-term value hinges on successful development and regulatory approval of VYD2311 and VMS063.
Risk Factors
- Delayed timeline for VYD2311 results increases uncertainty and extends cash runway needs.
- VMS063 is in early development with no clinical data; high risk of failure in later stages.
- Forward-looking statements dominate; lack of concrete data limits near-term upside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270803 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $0.8800 $0.8441 | ▼ −4.08% | ▼ −5.26% | $0.8221 (−6.58%) |
Aug 17, 2026 6w ago | 144 | $0.8680 $0.8198 | ▼ −5.55% | ▼ −4.56% | $0.8221 (−5.29%) |
Jul 6, 2026 12w ago | 8-K | $0.8340 $0.5350 | ▲ +35.85% | ▲ +35.29% | $0.8221 (+1.43%) |
Jun 16, 2026 15w ago | Press Release | $0.8918 $0.8008 | ▼ −10.20% | ▼ −10.40% | $0.8221 (−7.82%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.8125 $0.8037 | ▼ −1.08% | ▼ −2.97% | $0.8221 (+1.18%) |
Jun 9, 2026 16w ago | Press Release | $0.9900 $0.9418 | ▼ −4.87% | ▼ −6.32% | $0.8221 (−16.96%) |
Jun 1, 2026 17w ago | Press Release | $1.22 $0.8724 | ▼ −28.49% | ▼ −27.19% | $0.8221 (−32.61%) |
May 14, 2026 20w ago | 8-K | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
May 14, 2026 20w ago | Press Release | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
Apr 9, 2026 25w ago | 8-K | $1.78 $1.46 | ▼ −17.98% | ▼ −25.55% | $0.8221 (−53.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access